Categories: News

HMNC Brain Health to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

MUNICH, Germany, Sept. 07, 2021 (GLOBE NEWSWIRE) — HMNC Brain Health (“HMNC” or the “company”), a clinical stage biopharma company pioneering the development of personalized therapies powered by predictive companion diagnostics, announced today that Chief Executive Officer, Benedikt von Braunmühl, Chief Clinical Development Officer, Dr. Hans Eriksson and Head of Operations, Dr. Maximilian Döbler will present at the H.C. Wainwright 23rd Annual Global Investment Conference. HMNC Brain Health’s virtual presentation will be available beginning Monday, September 13th at 7:00am Eastern Time through Wednesday, September 15th and is accessible through the following webcast link: https://journey.ct.events/view/573f15f1-a6b8-4ae4-96e2-3a586b52b0b8.

In addition, HMNC Brain Health’s management team will participate in virtual one-on-one meetings throughout the day. To schedule a meeting or to request further information on the conference, please contact your H.C. Wainwright representative.

A webcast of the presentation will be available on the HMNC Brain Health Website for 90 days through the above webcast link.

About HMNC Brain Health

HMNC Brain Health (HMNC Holding GmbH) is a biotech company pioneering in developing personalized therapies powered by predictive companion diagnostics, leading to far shorter treatments and higher remission. The company develops a unique pipeline for targeting both major depressive disorder (MDD) and treatment-resistant depression (TRD). HMNC Brain Health is located at one of the leading European biotech hubs in Munich and backed by renowned family offices. The company now enters the next stage of its development with a large-scale licensing and fundraising agenda.

Media Contacts
Alexander Schmidt (Europe)
+49 151 22 99 39 765
alexander.schmidt@gaulyadvisors.com 

Anne Donohoe (U.S.)
+1 212-896-1265
hmnc@kcsa.com 

Investor Contact (U.S.)
Tim Regan / Rory Rumore
+1 347-487-6788
tregan@kcsa.com / rrumore@kcsa.com

Staff

Recent Posts

Babson Diagnostics Wins Best Abstract Award at 2025 EFLM Preanalytical Conference

EFLM recognizes Babson Diagnostics for innovations in sample collection and preparation AUSTIN, TX / ACCESS…

11 minutes ago

New Obesity Medicine Association Initiative Aims to Scale High-Impact Obesity Healthcare Improvements Nationwide

Centennial, Colorado--(Newsfile Corp. - December 18, 2025) - The Obesity Medicine Association (OMA) is pleased…

1 hour ago

Attune’s to Support Poppy Health’s $38M ARPA-H BREATHE Project in the U.S. Schools

VIENNA, Va., Dec. 18, 2025 /PRNewswire/ -- Attune announced today that the company will play…

3 hours ago

Attune’s to Support Poppy Health’s $38M ARPA-H BREATHE Project in the U.S. Schools

VIENNA, Va., Dec. 18, 2025 /PRNewswire/ -- Attune announced today that the company will play…

3 hours ago

Invacare® America Division ASL Launches Revolutionary iON Integrated Drive Control System to Help Enhance Wheelchair Users’ Independence and Mobility

New platform integrates wireless connectivity, communications and navigation to help enhance users' control over activities…

3 hours ago

Alleva Introduces InCheck: Transforming Behavioral Health Compliance Into a Year-Round System

LAGUNA NIGUEL, Calif., Dec. 18, 2025 /PRNewswire/ -- Alleva, a leader in behavioral health technology, announced…

3 hours ago